Moderna touts 'superior' antibody levels against Omicron for authorized Covid-19 bivalent booster
In September, Moderna received FDA emergency use authorization for its BA.4/BA.5-targeting bivalent booster vaccine, mRNA-1273.222, based on preclinical data for the shot as well as Phase II/III clinical trial data studying a similar bivalent booster targeting the Omicron BA.1 subvariant.
Now, the mRNA biotech says it has positive clinical data on mRNA-1273.222 itself to burnish the profile of the Covid-19 vaccine.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.